Supplementary file 1_Tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a single-center propensity-weighted cohort study.docx

Stabilized average-treatment-effect weights were truncated at the 1st and 99th percentiles. We report weighted risks, risk differences (RDs), odds ratios (ORs), and robust 95% confidence intervals (CIs). Secondary neurological/workflow and safety outcomes were adjusted within separate families using the Holm procedure.</p>Results<p>After weighting, 90-day functional independence was 77.9% with tenecteplase and 81.3% with alteplase (RD, −3.5 percentage points; 95% CI, −17.0 to 10.1; p = 0.616; OR, 0.81; 95% CI, 0.36–1.82).

Holm-adjusted p values for the other functional outcomes were 1.000. The weighted mean difference in door-to-needle time was −5.0 min (95% CI, −9.0 to −0.9; unadjusted p = 0.017; Holm-adjusted p = 0.068). Day-7 early neurological deterioration occurred in no tenecteplase recipient and nine alteplase recipients (weighted RD, −5.1 percentage points; 95% CI, −8.5 to −1.7; Holm-adjusted p = 0.016).

SITS-MOST symptomatic intracranial hemorrhage occurred in four patients, with a weighted RD of 0.2 percentage points (95% CI, −1.7 to 2.1).</p>Conclusion<p>Tenecteplase was not associated with greater 90-day functional independence in this propensity-weighted cohort. No clear between-group difference was observed in major hemorrhagic outcomes. DNT was shorter before multiplicity adjustment, and day-7 deterioration was less frequent after adjustment within the secondary neurological/workflow family.</p>